Discover 117 paid clinical trials in Billings, Montana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 117
Active & Responsive
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
for
Metastatic Dedifferentiated Liposarcoma,
Location: Billings MT, Bozeman MT, Great Falls MT, Anaconda MT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06422806
Phase3, Recruiting
Active & Responsive
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
for
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver,
Location: Billings MT, Salt Lake City UT, Denver CO, Littleton CO,
Sponsor: Massive Bio, Inc.
Sex: All
Age: 0+
Code: NCT03452774
Recruiting
Active & Responsive
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
for
Breast Neoplasms, Breast Cancer
Location: Billings MT, Tigard OR, Santa Monica CA, Skokie IL,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06797635
Phase2, Recruiting
Active & Responsive
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
for
Prostate Cancer, Prostatic Neoplasms
Location: Billings MT, Aurora CO, Grand Island NE, Seattle WA,
Sponsor: Merck Sharp & Dohme LLC
Sex: Male
Age: 18+
Code: NCT06925737
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
for
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma,
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Fort Collins CO, Boise ID, Loveland CO,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06058377
Phase3, Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
for
Fallopian Tube Endometrioid Adenocarcinoma,
Location: Billings MT, Cody WY, Bozeman MT, Great Falls MT,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT06580314
Phase3, Recruiting
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer